爱博医疗(688050) - 2023 Q3 - 季度财报

Cash Flow and Operating Activities - The net cash flow from operating activities for Q3 2023 was ¥130,766,218.86, a decrease of 36.3% compared to ¥205,406,732.69 in Q3 2022[1] - Total cash inflow from operating activities amounted to ¥678,861,084.50, up from ¥474,811,307.52 in the previous year, representing a 42.9% increase[1] - Cash outflow from operating activities totaled ¥548,094,865.64, compared to ¥269,404,574.83 in Q3 2022, indicating a significant increase of 103.5%[1] - The company’s cash flow from operating activities was impacted by increased payments to employees, which rose to ¥140,176,655.45 from ¥92,835,717.96, a 50.9% increase[1] - Cash flow from operating activities for the first three quarters of 2023 was ¥658,874,534.30, compared to ¥441,629,159.45 in 2022, representing an increase of 49.2%[36] - Net cash flow from operating activities decreased by 36.34%, despite a 49.19% increase in cash received from sales, attributed to higher procurement of raw materials and increased R&D expenses[79] Cash and Cash Equivalents - Cash and cash equivalents at the end of Q3 2023 reached ¥552,002,340.36, up from ¥257,255,287.55 at the end of Q3 2022, marking a 114.3% increase[4] - The company's cash and cash equivalents as of September 30, 2023, were CNY 1,020,241 million, slightly down from CNY 1,061,295 million at the end of 2022[49] Investment Activities - The company reported a net cash flow from investing activities of ¥1,530,000,000.00, down from ¥1,785,000,000.00 in the same period last year[1] - Cash inflow from investment activities totaled CNY 1,576 million, while cash outflow was CNY 1,451 million, resulting in a net cash inflow of CNY 125 million[38] Financing Activities - The total cash outflow from financing activities was ¥79,758,687.49, compared to ¥47,701,479.33 in Q3 2022, reflecting a 67.2% increase[4] Financial Position - The company's total liabilities as of September 30, 2023, were ¥351,483,674.90, an increase from ¥324,304,991.47 at the end of the previous year[17] - The total equity attributable to shareholders increased to ¥2,076,197,761.21 from ¥1,860,185,637.42, representing an increase of 11.6%[17] - The company's total assets as of September 30, 2023, were ¥2,501,579,781.01, compared to ¥2,244,446,364.23 at the end of the previous year, indicating a growth of 11.5%[17] - The total liabilities increased to CNY 1,020,240 million, reflecting ongoing investments and operational growth[49] Revenue and Profit - Total operating revenue for the first three quarters of 2023 reached ¥668,099,047.91, a significant increase of 51.5% compared to ¥441,315,587.20 in the same period of 2022[28] - Net profit for the third quarter of 2023 was ¥243,656,164.45, compared to ¥193,070,920.68 in the same quarter of 2022, representing a growth of 26.2%[33] - The company reported a total profit of ¥277,228,123.96 for the third quarter of 2023, compared to ¥231,777,086.15 in the same quarter of 2022, reflecting a growth of 19.6%[33] - Net profit attributable to shareholders was CNY 8,879 million, reflecting a 19.70% increase year-over-year[37] - Net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 32.54%, supported by revenue growth, although net profit growth lagged behind revenue due to increased operating costs and expenses[79] Expenses - Total operating costs for the first three quarters of 2023 were ¥402,850,711.88, up from ¥225,958,723.61 in 2022, reflecting a 78.3% increase[28] - Research and development expenses for the first three quarters of 2023 totaled ¥64,674,073.63, compared to ¥43,713,119.60 in 2022, marking a 47.8% increase[28] - Sales expenses for the first three quarters of 2023 were ¥126,933,548.78, up from ¥66,533,278.64 in 2022, indicating an increase of 90.8%[28] - The company’s R&D expenses for the current period were CNY 63,248 million, compared to CNY 33,290 million in the same period last year, indicating a focus on innovation[49] - Research and development expenses totaled 3,227.96 million RMB, a significant increase of 46.34% compared to the previous period[76] Shareholder Information - The company had a total of 8,838 common shareholders at the end of the reporting period[69] - Basic earnings per share for the third quarter of 2023 were ¥2.40, an increase from ¥1.88 in the same quarter of 2022[34] - The basic earnings per share were 0.84 RMB, representing an 18.31% increase from the previous period[76] Acquisitions - The company completed the acquisition of a 51% stake in Fujian Youni Kang Optical Co., Ltd., which has now become a subsidiary[44] Impairment Loss - The company experienced a credit impairment loss of ¥5,264,186.33 in the third quarter of 2023, compared to a loss of ¥4,499,076.55 in the same quarter of 2022[31]